1. In Vivo
  2. >>Business Strategy

Express Scripts Buys ValueRx

Just over a year ago, the acquisition of managed care specialist ValueHealth by hospital giant Columbia/HCA seemed a match made in heaven--and a new way of thinking about the way to put pharmacy benefit management in context after the failed drug company acquisitions of 1993-4. Now Columbia is spinning ValueRx off. The new deal makes Express Scripts the largest independent PBM in the country and both solidifies and diversifies its customer base. But it also likely spells the end to the PBM alliances of the past several years.

Some PBM executives are asking whether Express Scripts Inc. 's $445 million acquisition of ValueRx is the beginning of a long-anticipated consolidation of the PBM industry, a consolidation that has been more talk than action since the now-ancient drug company acquisitions of 1993-1994 [See Deal]. But the deal might best be seen as the end of something quite different for the PBM industry, an end to the experimentation and mergers that have taken place over the past couple of years.

Adding ValueRx increases Express Scripts' network prescription claims by 75% and more than doubles its mail service prescriptions. In the process, Express Scripts becomes the largest independent PBM (i.e., not...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

Laying The Foundation And Overcoming Prerequisites To Establish AI Within Health Care

 
• By Mike King

As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.